Tag: Actinic Keratosis

Three-day Field Treatment with Ingenol Disoxate (LEO 43204) for Actinic Keratosis: A Phase II Trial

Three-day Field Treatment with Ingenol Disoxate (LEO 43204) for Actinic Keratosis: A Phase II Trial

| December 1, 2017

by Daniel M. Siegel, MD; Stephen Tyring, MD, PhD; Walter K. Nahm, MD, PhD; Marie Louise Østerdal, MSc; Astrid H. Petersen, PhD;  and Brian Berman, MD, PhD Dr. Siegel is with Long Island Skin Cancer and Dermatologic Surgery in New York, New York. Dr. Tyring is with the Center for Clinical Studies in Houston, Texas. […]

Continue Reading

Three-Day Field Treatment with Ingenol Disoxate (LEO 43204) for Actinic Keratosis: Cosmetic Outcomes and Patient Satisfaction from a Phase II Trial

Three-Day Field Treatment with Ingenol Disoxate (LEO 43204) for Actinic Keratosis: Cosmetic Outcomes and Patient Satisfaction from a Phase II Trial

| November 1, 2017

by Brian Berman, MD, PhD; Stephen Tyring, MD, PhD; Walter K. Nahm, MD, PhD; Marie Louise Østerdal, MSc; Astrid H. Petersen, PhD; and Daniel M. Siegel, MD Dr. Berman is Co-Director at Center for Clinical and Cosmetic Research in Aventura, Florida. Dr. Tyring is Medical Director at the Center for Clinical Studies at University of […]

Continue Reading

Noninvasive Long-term Monitoring of Actinic Keratosis and Field Cancerization Following Treatment with Ingenol Mebutate Gel 0.015%

Noninvasive Long-term Monitoring of Actinic Keratosis and Field Cancerization Following Treatment with Ingenol Mebutate Gel 0.015%

| October 1, 2017

by Orit Markowitz, MD; Katie Wang, DO; Amanda Levine, MD; Michelle Schwartz, BA;  Sumeet Minhas, BA; Eleanor Feldman, BA; and Daniel M. Siegel, MD Drs. Markowitz, Wang, Levine; Ms. Minhas; and Ms. Schwartz and Ms. Feldman are associated with the Department of Dermatology, SUNY Downstate Medical Center, New York, New York; the Department of Dermatology, […]

Continue Reading

A Prospective Pilot Clinical Trial to Evaluate the Efficacy and Safety of Topical Therapy with Ingenol Mebutate Gel 0.015% for Actinic Keratosis on an Expanded Area of the Chest

A Prospective Pilot Clinical Trial to Evaluate the Efficacy and Safety of Topical Therapy with Ingenol Mebutate Gel 0.015% for Actinic Keratosis on an Expanded Area of the Chest

| August 1, 2017

by Douglas C. Wu, MD, PhD; Isabella Guiha, BSc; and Mitchel P. Goldman, MD Drs. Wu and Goldman and Ms. Guiha are with Cosmetic Laser Dermatology, San Diego, California. J Clin Aesthet Dermatol. 2017;10(8):31–36 Funding: This study was sponsored and funded by LEO Pharma. Disclosures: The authors have no conflicts of interest relevant to the […]

Continue Reading

The Impact of the Current United States Guidelines on the Management of Actinic Keratosis: Is It Time for an Update?

The Impact of the Current United States Guidelines on the Management of Actinic Keratosis: Is It Time for an Update?

| November 5, 2010 | 0 Comments

George Martin, MD Dermatology and Laser Center of Maui, Kihei, Hawaii

Continue Reading

Actinic Keratosis Treatment as a Key Component of Preventive Strategies for Nonmelanoma Skin Cancer

Actinic Keratosis Treatment as a Key Component of Preventive Strategies for Nonmelanoma Skin Cancer

| June 10, 2010 | 0 Comments

Joel L. Cohen, MD Dr. Cohen is from the Department of Dermatology, University of Colorado, Denver; AboutSkin Dermatology and DermSurgery, Englewood, Colorado

Continue Reading

Diclofenac Sodium 3% Gel for the Treatment of Actinic Keratosis Case-based Experience

| March 26, 2010 | 0 Comments

Proceedings from a Clinical Dermatology Roundtable. Supplement to the March 2010 issue of The Journal of Clinical and Aesthetic Dermatology This supplement was supported by Pharmaderm, a division of Nycomed US Inc. Click hyperlink below to access supplement: Diclofenac Sodium 3% Gel for the Treatment of Actinic Keratosis: Case-based Experience –

Continue Reading